Trials / Completed
CompletedNCT00782093
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | volociximab | volociximab intravitreal injection |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2008-10-31
- Last updated
- 2024-02-21
Source: ClinicalTrials.gov record NCT00782093. Inclusion in this directory is not an endorsement.